MYCN and neuroblastoma: In summary, our in vivo data demonstrate that GSK3326593 is a highly selective Prmt5 inhibitor, and that inhibition of Prmt5 in MYCN-dependent mouse neuroblastoma compromises the fitness and proliferation of tumour cells, resulting in their increased survival.